Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 ,inter alia, to consider and approve Unaudited Financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has informed BSE that its Board of Directors will meet on August 12, 2025. The main agenda is to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the first quarter ended June 30, 2025. Other business items may also be discussed. This is a routine regulatory filing under SEBI's Listing Obligations and Disclosure Requirements. No financial figures or details have been disclosed in this intimation.
This is a procedural announcement with no immediate impact on the stock. Investors should await the actual Q1 results on or after August 12, 2025 for any financial insights. Quarterly results for diagnostics companies often hint at testing volume trends and pricing.